We begin with a discussion about our article of the week which comes from The Lancet and is entitled “Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.”
Then we discuss the challenges and recovery after having brain aneurysm and talk about the first disease modifying FDA approved drug for Alzheimer’s disease. After that, we take a look at liver transplant in children. Finally, we go over psoriasis and briefly go over risk factors and treatments.